Device Trial Radar · NCT05844826
Evaluation of the Microbiome in Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
40
Actual
Start
Jun 26, 2023
Primary completion
Apr 24, 2024
Study completion Apr 24, 2024
Sponsor
- Lead sponsor
- Nimble Science Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- IGY Life Sciences
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.
Conditions
- Multiple Sclerosis
Interventions
SIMBA CapsuleDevice
Participants will swallow capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- 16s microbiome sequencing and LC-MS metabolomic analysis will be performed on these samples to compare gut microbiome and metabolite profiles of healthy control and diagnosed MS patientsTime frame: baseline
- Comparison of blood samples from Multiple Sclerosis (MS) and healthy control participants for biomarkers of inflammation, as analysed using ELISA, protenomic methods, and commercially available assays.Time frame: baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Calgary
Calgary, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.